Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RCCs more than 50% cystic have good prognosis

Kashan M et al. The Journal of Urology 1 March 2018

Key clinical point: Patients with unifocal cystic renal cell carcinoma evaluated using a standardized radiologic threshold of more than 50% cystic on imaging have an excellent prognosis on both active surveillance and following surgical resection.

Major finding: Among 38 patients on active surveillance, growth rate was found to be 1.0 mm/year overall and 2.3 mm/year for the solid component. After a median follow-up of over 4 years, there was no evidence of recurrence or metastasis from cystic renal cell carcinoma.

Study details: Of the 138 cases of cystic renal cell carcinoma identified, 102 (73.9%) were renal cell carcinoma and 36 (26.1%) benign masses. Most tumors were Fuhrman grade 1-2 (77.5%), less than or equal to pT2 stage (83.4%) with clear cell histology (65.9%).

Disclosures: The authors had no relevant financial disclosures.

Source: Kashan M et al. The Journal of Urology 1 March 2018


Kashan M et al. The Journal of Urology 1 March 2018

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44.

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in Renal Cell Carcinoma

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617